BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35792876)

  • 1. Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset.
    Febres-Aldana CA; Chang JC; Ptashkin R; Wang Y; Gedvilaite E; Baine MK; Travis WD; Ventura K; Bodd F; Yu HA; Quintanal-Villalonga A; Lai WV; Egger JV; Offin M; Ladanyi M; Rudin CM; Rekhtman N
    Clin Cancer Res; 2022 Nov; 28(21):4702-4713. PubMed ID: 35792876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
    Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
    Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical correlation of extensive-stage small-cell lung cancer genomics.
    Dowlati A; Lipka MB; McColl K; Dabir S; Behtaj M; Kresak A; Miron A; Yang M; Sharma N; Fu P; Wildey G
    Ann Oncol; 2016 Apr; 27(4):642-7. PubMed ID: 26802149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.
    Dowlati A; Abbas A; Chan T; Henick B; Wang X; Doshi P; Fu P; Patel J; Kuo F; Chang H; Balli D
    JCO Precis Oncol; 2022 Aug; 6():e2200257. PubMed ID: 36044718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer.
    Wildey G; Shay AM; McColl KS; Yoon S; Shatat MA; Perwez A; Spainhower KB; Kresak AM; Lipka M; Yang M; Behtaj M; Fu P; Alahmadi A; Mneimneh W; Abbas A; Dowlati A
    Mol Cancer Ther; 2023 Feb; 22(2):264-273. PubMed ID: 36399634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
    Shapiro GI; Edwards CD; Kobzik L; Godleski J; Richards W; Sugarbaker DJ; Rollins BJ
    Cancer Res; 1995 Feb; 55(3):505-9. PubMed ID: 7834618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
    Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
    Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted pharmacologic inhibition of S-phase kinase-associated protein 2 (SKP2) mediated cell cycle regulation in lung and other RB-Related cancers: A brief review of current status and future prospects.
    Elahi AH; Morales CS; Xu XL; Eliades A; Patsalis PC; Abramson DH; Jhanwar SC
    Adv Biol Regul; 2023 May; 88():100964. PubMed ID: 37004354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
    Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
    J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
    Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
    Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
    Burns L; Tukachinsky H; Raskina K; Huang RSP; Schrock AB; Sands J; Kulke MH; Oxnard GR; Tapan U
    Lung Cancer; 2024 Feb; 188():107454. PubMed ID: 38159439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation and synthetic lethality of exclusive RB1 and CDKN2A mutations in lung cancer.
    Kim N; Song M; Kim S; Seo Y; Kim Y; Yoon S
    Int J Oncol; 2016 Jan; 48(1):367-75. PubMed ID: 26647789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Pathological Characteristics of
    Frank R; Scheffler M; Merkelbach-Bruse S; Ihle MA; Kron A; Rauer M; Ueckeroth F; König K; Michels S; Fischer R; Eisert A; Fassunke J; Heydt C; Serke M; Ko YD; Gerigk U; Geist T; Kaminsky B; Heukamp LC; Clement-Ziza M; Büttner R; Wolf J
    Clin Cancer Res; 2018 Jul; 24(13):3087-3096. PubMed ID: 29615460
    [No Abstract]   [Full Text] [Related]  

  • 15. POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.
    Baine MK; Febres-Aldana CA; Chang JC; Jungbluth AA; Sethi S; Antonescu CR; Travis WD; Hsieh MS; Roh MS; Homer RJ; Ladanyi M; Egger JV; Lai WV; Rudin CM; Rekhtman N
    J Thorac Oncol; 2022 Sep; 17(9):1109-1121. PubMed ID: 35760287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines.
    Kelley MJ; Nakagawa K; Steinberg SM; Mulshine JL; Kamb A; Johnson BE
    J Natl Cancer Inst; 1995 May; 87(10):756-61. PubMed ID: 7563154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.
    Bhateja P; Chiu M; Wildey G; Lipka MB; Fu P; Yang MCL; Ardeshir-Larijani F; Sharma N; Dowlati A
    Cancer Med; 2019 Apr; 8(4):1459-1466. PubMed ID: 30773851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations.
    Ogino A; Choi J; Lin M; Wilkens MK; Calles A; Xu M; Adeni AE; Chambers ES; Capelletti M; Butaney M; Gray NS; Gokhale PC; Palakurthi S; Kirschmeier P; Oxnard GR; Sholl LM; Jänne PA
    Mol Oncol; 2021 Jan; 15(1):27-42. PubMed ID: 32191822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.
    Modi S; Kubo A; Oie H; Coxon AB; Rehmatulla A; Kaye FJ
    Oncogene; 2000 Sep; 19(40):4632-9. PubMed ID: 11030152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of Rb1, cyclin D1 and p16 immunohistochemistry expression to distinguish lung small-cell carcinoma and large-cell neuroendocrine carcinoma.
    Papaxoinis G; Bille A; McLean E; Nonaka D
    Histopathology; 2022 Aug; 81(2):205-214. PubMed ID: 35544410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.